Vicore Pharma Adds Veteran Pharma Executive Peter Guenter to Board Ahead of Key IPF Milestone

An update from Vicore Pharma Holding AB ( (SE:VICO) ) is now available.

Vicore Pharma has appointed veteran pharmaceutical executive Peter Guenter to its Board of Directors as it advances its lead drug candidate buloxibutid toward a key late-stage data readout. Guenter, a former CEO of Merck Healthcare KGaA and Almirall with more than 20 years at Sanofi, brings deep commercial and strategic experience that Vicore says will support portfolio building and late-stage development and commercialization plans.

Company leaders describe the appointment as a strong endorsement of Vicore’s prospects in idiopathic pulmonary fibrosis, where buloxibutid is positioned as a differentiated therapy for a disease with significant unmet need. Guenter highlighted Vicore’s scientific and operational foundations and signaled his intent to help steer the company through a pivotal period as it seeks to deliver a potentially transformational treatment to patients and strengthen its strategic position in the respiratory and fibrotic disease market.

The most recent analyst rating on (SE:VICO) stock is a Buy with a SEK38.00 price target. To see the full list of analyst forecasts on Vicore Pharma Holding AB stock, see the SE:VICO Stock Forecast page.

More about Vicore Pharma Holding AB

Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company focused on developing a novel class of angiotensin II type 2 receptor agonists for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis. Its lead candidate, buloxibutid, is an oral, first-in-class ATRAG with U.S. Orphan Drug and Fast Track status, now in a global Phase 2b trial, and the company is listed on Nasdaq Stockholm under the ticker VICO.

Average Trading Volume: 520,577

Technical Sentiment Signal: Sell

Current Market Cap: SEK2.81B

Find detailed analytics on VICO stock on TipRanks’ Stock Analysis page.